PMID- 26187773
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20220408
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 75
IP  - 12
DP  - 2015 Aug
TI  - Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase 
      Inhibitors in the UK.
PG  - 1335-48
LID - 10.1007/s40265-015-0434-6 [doi]
AB  - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as 
      gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment 
      of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a 
      proven benefit in terms of higher response rate, delaying progression and 
      improvement of quality of life over palliative platinum-based chemotherapy. The 
      most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and 
      stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are 
      usually mild, but if they become moderate or severe, they can have a negative 
      impact on the patient's quality of life (QOL) and lead to dose modifications or 
      drug discontinuation. Appropriate management of AEs, including prophylactic 
      measures, supportive medications, treatment delays and dose reductions, is 
      essential. A consensus meeting of a UK-based multidisciplinary panel composed of 
      medical and clinical oncologists with a special interest in lung cancer, 
      dermatologists, gastroenterologists, lung cancer nurse specialists and oncology 
      pharmacists was held to develop guidelines on prevention and management of 
      cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and 
      mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines 
      detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. 
      Although the focus of the guidelines is to support healthcare professionals in UK 
      clinical practice, it is anticipated that the management strategies proposed will 
      also be applicable in non-UK settings.
FAU - Califano, R
AU  - Califano R
AD  - Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation 
      Trust, Wilmslow Road, Manchester, M20 4BX, UK, raffaele.califano@christie.nhs.uk.
FAU - Tariq, N
AU  - Tariq N
FAU - Compton, S
AU  - Compton S
FAU - Fitzgerald, D A
AU  - Fitzgerald DA
FAU - Harwood, C A
AU  - Harwood CA
FAU - Lal, R
AU  - Lal R
FAU - Lester, J
AU  - Lester J
FAU - McPhelim, J
AU  - McPhelim J
FAU - Mulatero, C
AU  - Mulatero C
FAU - Subramanian, S
AU  - Subramanian S
FAU - Thomas, A
AU  - Thomas A
FAU - Thatcher, N
AU  - Thatcher N
FAU - Nicolson, M
AU  - Nicolson M
LA  - eng
GR  - 13044/CRUK_/Cancer Research UK/United Kingdom
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics/pathology
MH  - Consensus
MH  - Dose-Response Relationship, Drug
MH  - ErbB Receptors/*antagonists & inhibitors/genetics/metabolism
MH  - Gastrointestinal Diseases/chemically induced/diagnosis/*therapy
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Molecular Targeted Therapy
MH  - Mutation
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - Quality of Life
MH  - Risk Factors
MH  - Signal Transduction/drug effects
MH  - Skin Diseases/chemically induced/diagnosis/*therapy
MH  - Treatment Outcome
MH  - United Kingdom
PMC - PMC4532717
EDAT- 2015/07/19 06:00
MHDA- 2016/05/20 06:00
PMCR- 2015/07/18
CRDT- 2015/07/19 06:00
PHST- 2015/07/19 06:00 [entrez]
PHST- 2015/07/19 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
PHST- 2015/07/18 00:00 [pmc-release]
AID - 434 [pii]
AID - 10.1007/s40265-015-0434-6 [doi]
PST - ppublish
SO  - Drugs. 2015 Aug;75(12):1335-48. doi: 10.1007/s40265-015-0434-6.